AzurRx BioPharma

[Available On-Demand]
AzurRx BioPharma is a clinical stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). The company is headquartered in Delray Beach, Florida, with scientific operations in Langlade, France and clinical operations in Hayward, California.
Ticker:
AZRX
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
MS1819
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
AzurRx BioPharma Inc.